Showing results (151-160 of 3,454) with videos related to

Sort By:
Pageof 346
Expert Opinion on Biological Therapy|July 23, 2004
90Yttrium-ibritumomab tiuxetan: a novel treatment for non-Hodgkin's lymphomaKristie A Blum, Nancy L Bartlett
Expert Opinion on Biological Therapy|July 23, 2004
Gene therapy approaches to prolonging corneal allograft survivalKeryn A Williams, Claire F Jessup, Douglas J Coster
Expert Opinion on Biological Therapy|July 23, 2004
Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approvalRobert J Desnick
Expert Opinion on Biological Therapy|January 17, 2022
Prostate cancer immunotherapyIraklis Mitsogiannis, Lazaros Tzelves, Athanasios Dellis, et al.
Expert Opinion on Biological Therapy|September 5, 2022
Advancements in ocular gene therapy delivery: vectors and subretinal, intravitreal, and suprachoroidal techniquesKyle D Kovacs, Thomas A Ciulla, Szilárd Kiss
Expert Opinion on Biological Therapy|January 19, 2022
Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational studyMarco Galluzzo, Marina Talamonti, Laura Atzori, et al.
Expert Opinion on Biological Therapy|January 21, 2022
Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumorsAlex W Liu, Alexander Z Wei, Ashray B Maniar, et al.
Expert Opinion on Biological Therapy|October 7, 2022
Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm clinical trial, then an extension phase of AVT02 administered with a prefilled syringeNemanja Damjanov, Nana Kirvalidze, Nana Kurashvili, et al.
Expert Opinion on Biological Therapy|August 30, 2022
GP2017-HCF, a high concentration formulation, demonstrates similar pharmacokinetics, immunogenicity and safety to GP2017, an approved adalimumab biosimilarOliver von Richter, Terry O'Reilly, Davide Guerrieri, et al.
Expert Opinion on Biological Therapy|November 3, 2021
Toward the integration of biosimilars into pediatric rheumatology: adalimumab ABP 501 experience of PeRA research groupFatma Gül Demirkan, Kadir Ulu, Kübra Öztürk, et al.
Pageof 346